Healthcare Industry News: K2M
News Release - October 23, 2012
K2M to Showcase Comprehensive Portfolio at 2012 North American Spine Society Annual MeetingCompany Marks Ascent to Largest Privately Held Spinal Device Company with Ongoing Commitment to Growth through Innovation
LEESBURG, Va.--(Healthcare Sales & Marketing Network)--K2M, Inc., the largest privately held spinal device company in the world focused on developing innovative solutions for the treatment of complex spinal pathologies and minimally invasive procedures, today announced that with the recent addition of multiple breakthrough technologies, K2M offers a market leading comprehensive product portfolio to be exhibited at the North American Spine Society (NASS) Annual Meeting.
“As the fastest growing and largest privately held company in spine, it is critical that K2M continues to invest in research and development with the ongoing vision to constantly provide more efficient and higher-quality products and services,” stated Eric Major, K2M’s President and CEO. “Through strong financial investments and continued innovation K2M continues to expand our global footprint by offering next generation technologies to surgeons in all regions of the world.”
K2M’s portfolio consists of over 40 unique and differentiated products, and the company maintains a diligent focus on the protection of these technologies by continuing to invest in a portfolio of over 375 issued and pending patents. At the 2011 NASS Annual Meeting, K2M introduced nine new products and promised additional developments including a line of biologic products as well as the introduction of a breakthrough technology to address the most challenging complex deformities.
This year, technologies showcased at the meeting will build upon K2M’s proven track record as a leader in the complex and minimally invasive approaches to the spine, as well as deliver on the company’s commitment to offering solutions for the full spectrum of spinal pathologies. Highlights from K2M to be showcased at NASS for the first time will include:
- K2M’s breakthrough Rail 4D™ Technology to address the most complex spinal curves. Inspired by structural I-beam geometry, the Rail provides enhanced structural rigidity with particular strength characteristics for maintenance of saggital balance. The Rail 4D system is lower-profile than traditional set screw based technologies.
- MESA® Small Stature Spinal System, a Ø4.5 mm line extension of the company’s revolutionary low profile, zero torque family of products marking K2M’s first pedicle screw available for small stature patients. With a new enhanced dual lead thread and ergonomic instrumentation, it is poised to address the most difficult correction maneuvers.
- VESUVIUS™ Osteobiologic Systems and new additions to the VIKOS® Allograft Systems, through a partnership with LifeNet Health®. The VESUVIUS family of products is designed specifically to enhance bone regeneration after spine surgery. The VESUVIUS Fiber product offering is a unique biologic designed to provide optimized porosity, surface area, and structure, translating to optimal osteoinductive potential by maximizing exposure of growth factors. Additionally, the portfolio offers a variety of configurations and sizes to meet surgeons’ clinical needs, while K2M’s VIKOS Cervical now includes unicortical, tricortical, and iliac crest grafts, as well as VIKOS Void Fillers and VIKOS Shafts.
- SANTORINI™ Corpectomy Cage Systems, manufactured from biocompatible PEEK polymer to allow for an unobstructed view of the post-operative fusion. SANTORINI Solid offers an enlarged graft space, while SANTORINI Expandable allows for in-situ expansion with a locking clip to secure the desired height.
K2M, Inc. is the largest privately held spinal device company in the world focused on the research, development, and commercialization of innovative solutions for the treatment of complex spinal pathologies and minimally invasive procedures. The company is recognized as a global leader in providing unique technologies for the treatment of deformity, degenerative, trauma, and tumor spinal patients. K2M’s product development pipeline includes: spinal stabilization systems, minimally invasive systems, biologics, and other advancing technologies, such as motion preservation, annular repair, and nucleus replacement. Additional information is available online at www.K2M.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.